The Market Reports

Synopsis
The global market for Hemofiltration Basic Solution was estimated to be worth US$ 635 million in 2024 and is forecast to a readjusted size of US$ 1527 million by 2031 with a CAGR of 15.3% during the forecast period 2025-2031.
Hemofiltration replacement basic solution is a special drug for continuous blood purification. It is used to replace water and electrolytes in the body during hemofiltration treatment and replace part of the kidney function. The prescription ingredients of this product do not contain potassium ions and lactate, which is convenient for the rapid preparation of bicarbonate hemofiltration basic solution in clinical practice, avoids complications such as lactic acidosis and hyperkalemia, and stabilizes the internal environment of the body to the greatest extent.
The largest manufacturer of hemofiltration basic solution in China is Chengdu Qingshan Likang Pharmaceutical, holds a share over 80%.
Blood purification technology is a new medical technology developed in the late twentieth century on the basis of artificial kidneys for the treatment of chronic renal failure. It is a medical technology that draws the patient's blood out of the body, removes certain pathogenic substances in it through purification devices, purifies the blood, and achieves the purpose of treating certain diseases. It is often used in the treatment of patients with end-stage renal disease (uremia), critical illness, acute poisoning, etc. The basic treatment methods of blood purification include hemodialysis (HD), hemoperfusion (HP) or hemoadsorption (HA), hemofiltration (HF), plasma exchange (PE), immunoadsorption (IA), etc., as well as the combined application of multiple technologies above.
From the perspective of different populations, those over 65 years old account for nearly 44% of the total market size.
From the perspective of product market application, since blood filtration replacement basic fluid is mainly used for blood filtration treatment, most of them are continuous blood filtration at the bedside of critically ill patients in ICU wards. The market size of blood filtration replacement basic fluid for ICU has reached 80%.
This report aims to provide a comprehensive presentation of the global market for Hemofiltration Basic Solution, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Hemofiltration Basic Solution by region & country, by Type, and by Application.
The Hemofiltration Basic Solution market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemofiltration Basic Solution.
Market Segmentation
By Company
Huaren Pharmaceutical
Shijiazhuang No.4 Pharmaceutical
Chengdu Qingshan Likang Pharmaceutical
Segment by Type
Age: above 65
Age: between 45 and 64
Age: below 45
Segment by Application
ICU
Nephrology
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Hemofiltration Basic Solution manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Hemofiltration Basic Solution in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Hemofiltration Basic Solution in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index